PharmaCyte Biotech Inc (PMCB) Q2 2025 Earnings Report

- Revenue: N/A; Gross Profit: N/A; Operating Income: -1.10606 million with YoY increase of 21.56% and QoQ increase of 12.83% (interpreted as a narrowing loss versus the prior year quarter and improving sequentially). - Net Income: -1.46956 million; YoY: -152.67% (deterioration in bottom line vs year-ago period); QoQ: -106.27% (further deterioration versus prior quarter). - EPS: -0.39; YoY: -50.00%; QoQ: -120.53%. - Cash flow: Net cash used in operating activities -1.054735 million; Net cash from financing activities -10.740362 million; Cash at end of period 20.840056 million; Free cash flow: -1.054735 million. - Balance sheet: Total assets 55.098384 million; Total liabilities 11.647238 million; Total stockholders’ equity 43.451146 million; Cash and equivalents 20.840056 million; Intangible assets 1.549427 million; Long-term investments 24.855000 million; Current ratio 4.47; Net cash position -20.840056 million.